|  | | 3594 | Abatacept(Orencia®)forInjectionforIntravenousUse08.00.62m | Pharmacy (08) | 08.00.62m | 08.00.62 | 834bcbbf-eb2a-49a9-a954-5a4398bc345c | Abatacept (Orencia®) for Injection for Intravenous Use | Abatacept (Orencia®) for Injection for Intravenous Use | {"3595": {"Id":3595,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5693,"PolicyAttachmentPageName":"e8ec48ee-9ef9-4f21-adb1-0f967873d72c"},} |
| | | 3677 | Acupuncture(AmeriHealth)12.00.01g | Miscellaneous (12) | 12.00.01g | 12.00.01 | 69738b74-5838-4194-b77b-19438159b0a8 | Acupuncture (AmeriHealth) | Acupuncture (AmeriHealth) | {"3678": {"Id":3678,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":5771,"PolicyAttachmentPageName":"912f4a23-322e-4108-a3dd-90f618ad26d3"},} |
| | | 3303 | AcuteCareFacilityInpatientTransfers12.04.04a | Miscellaneous (12) | 12.04.04a | 12.04.04 | baf2b880-5954-469c-adfe-fcce98d1ed7e | Acute Care Facility Inpatient Transfers | Acute Care Facility Inpatient Transfers | |
| | | 3886 | Ado-TrastuzumabEmtansine(Kadcyla®)08.01.11g | Pharmacy (08) | 08.01.11g | 08.01.11 | 4c4e349b-96ae-4b67-8665-e39cf4b971d0 | Ado-Trastuzumab Emtansine (Kadcyla®) | Ado-Trastuzumab Emtansine (Kadcyla®) | {"3887": {"Id":3887,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":5900,"PolicyAttachmentPageName":"0b37c703-c120-4191-8b91-c926cacc5277"},} |
| | | 4174 | Agalsidasebeta(Fabrazyme®)08.00.69c | Pharmacy (08) | 08.00.69c | 08.00.69 | 6b63a7e1-4463-4e1e-b63d-9246fce9041a | Agalsidase beta (Fabrazyme®) | Agalsidase beta (Fabrazyme®) | |
| | | 3383 | AirAmbulanceServices12.04.03c | Miscellaneous (12) | 12.04.03c | 12.04.03 | c7c932d9-9c5e-4b7d-845e-a6b2b3a53835 | Air Ambulance Services | Air Ambulance Services | |
| | | 3393 | Alemtuzumab(Lemtrada®)08.01.22d | Pharmacy (08) | 08.01.22d | 08.01.22 | 8d15f836-a0d2-4303-acef-f981a139b95c | Alemtuzumab (Lemtrada®) | Alemtuzumab (Lemtrada®) | |
| | | 4265 | Alglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®)08.00.72k | Pharmacy (08) | 08.00.72k | 08.00.72 | db78fe85-fc99-4a2e-abea-24e3940e2471 | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ) | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ) | |
| | | 3199 | AllergyImmunotherapy07.00.21j | Medicine (07) | 07.00.21j | 07.00.21 | 5bebba01-0b42-45ed-ae07-f386ffcff954 | Allergy Immunotherapy | Allergy Immunotherapy | |
| | | 4201 | AllogeneicProcessedThymusTissue-agdc(Rethymic®)08.01.88 | Pharmacy (08) | 08.01.88 | 08.01.88 | 3a1f86ae-9d7b-4d18-a99c-b44ed0f6cd73 | Allogeneic Processed Thymus Tissue-agdc (Rethymic®) | Allogeneic Processed Thymus Tissue-agdc (Rethymic®) | |
| | | 4198 | AlloMap™MolecularExpressionTestingforHeartTransplantRejection(AmeriHealthAdministrators)06.02.29d | Pathology and Laboratory (06) | 06.02.29d | 06.02.29 | ee3acd73-2ead-4f72-a15c-bddfc95ed3c7 | AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (AmeriHealth Administrators) | AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (AmeriHealth Administrators) | |
| | | 3837 | Alpha1-AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91e | Pharmacy (08) | 08.00.91e | 08.00.91 | bb43de82-f71f-4625-aee6-50336e39320f | Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) | Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) | |
| | | 4207 | AlwaysBundledProcedureCodes00.01.52p | Administrative (00) | 00.01.52p | 00.01.52 | 1c16cded-b770-4aa4-b763-1204e1dc69d5 | Always Bundled Procedure Codes | Always Bundled Procedure Codes | {"4208": {"Id":4208,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":6316,"PolicyAttachmentPageName":"de168228-6f57-4957-8517-773585a1efd4"},"4209": {"Id":4209,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (Indicator B)","MPPolicyAttachmentInternalSourceId":6317,"PolicyAttachmentPageName":"fc8b0f8f-99ad-45c6-ad8c-86a0ae81d945"},"4210": {"Id":4210,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":6318,"PolicyAttachmentPageName":"488cf7e4-8069-4874-8105-a457b182dc12"},} |
| | | 3042 | AmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09g | Medicine (07) | 07.02.09g | 07.02.09 | c233d9c4-b48b-4763-a10b-7f4a06ccaad8 | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | |
| | | 3965 | AmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21h | Medicine (07) | 07.02.21h | 07.02.21 | 566dc299-1d7d-47a0-b25f-8aa0a7df906f | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | |
| | | 4185 | AnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagement01.00.12 | Anesthesia (01) | 01.00.12 | 01.00.12 | 980512de-305e-46eb-a71f-bd4469be1e29 | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | {"4186": {"Id":4186,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6198,"PolicyAttachmentPageName":"cf0f551d-36d2-4f0c-ba17-7977c609c05f"},} |
| | | 4168 | Anifrolumab-fnia(Saphnelo™)08.01.82b | Pharmacy (08) | 08.01.82b | 08.01.82 | a5a442c8-1c78-4320-8da4-c92a3ab15c17 | Anifrolumab-fnia (Saphnelo™) | Anifrolumab-fnia (Saphnelo™) | |
| | | 3456 | Ankle-Foot/Knee-Ankle-FootOrthoses05.00.39r | DME (05) | 05.00.39r | 05.00.39 | ec509307-9989-4a80-b1f1-e5d5eae25831 | Ankle-Foot/Knee-Ankle-Foot Orthoses | Ankle-Foot/Knee-Ankle-Foot Orthoses | {"3457": {"Id":3457,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":5437,"PolicyAttachmentPageName":"5d32ce1c-b867-42d3-b5ce-2492f31a60d6"},} |
| | | 2807 | ApheresisTherapy06.03.04n | Pathology and Laboratory (06) | 06.03.04n | 06.03.04 | b395fd09-303a-4b18-a74c-04bb56dc9226 | Apheresis Therapy | Apheresis Therapy | |
| | | 4254 | ApplicationandRemovalofTattoos11.08.05g | Surgery (11) | 11.08.05g | 11.08.05 | 8fad7e68-1f61-4469-8a09-0333356fb918 | Application and Removal of Tattoos | Application and Removal of Tattoos | |
| | | 3520 | Aprepitant(Cinvanti™),FosaprepitantDimeglumine(Emend®),Granisetron(Sustol®),andRolapitant(Varubi®)08.01.41c | Pharmacy (08) | 08.01.41c | 08.01.41 | 44db3f87-de94-4415-b8cf-8c8f3b56bd72 | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | {"3521": {"Id":3521,"MPAttachmentLetter":"A","Title":"Risk of Emesis Without Prophylaxis: Intravenous and Oral Antineoplastic Agents","MPPolicyAttachmentInternalSourceId":5660,"PolicyAttachmentPageName":"41416d06-beb2-4742-9635-590fcea6183c"},} |
| | | 4005 | AqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16j | Surgery (11) | 11.05.16j | 11.05.16 | cbae5cb1-bbc3-49be-a2a5-bdc81e91fd0c | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | {"4006": {"Id":4006,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":6070,"PolicyAttachmentPageName":"3634fac1-8298-4256-bf28-7fa3bd60cc08"},} |
| | | 3758 | ArtificialIntervertebralCervicalDiscInsertion(AmerihealthAdministrators)11.14.19p | Surgery (11) | 11.14.19p | 11.14.19 | 6ab357b1-349e-429e-bdfe-ec87420c4790 | Artificial Intervertebral Cervical Disc Insertion (Amerihealth Administrators) | Artificial Intervertebral Cervical Disc Insertion (Amerihealth Administrators) | |
| | | 3721 | ArtificialIntervertebralLumbarDiscInsertion11.15.31 | Surgery (11) | 11.15.31 | 11.15.31 | 6e26e848-ee5d-4b42-8215-06fa20219584 | Artificial Intervertebral Lumbar Disc Insertion | Artificial Intervertebral Lumbar Disc Insertion | |
| | | 4020 | AsparaginaseErwiniaChrysanthemi(Erwinaze®),asparaginaseerwiniachrysanthemi(recombinant)-rywn(Rylaze™)08.01.35e | Pharmacy (08) | 08.01.35e | 08.01.35 | 7d35bbfc-2050-4e90-b6e3-dda8ec8beb57 | Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) | Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) | |
| | | 3978 | AssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(AmeriHealthAdministrators)06.02.27m | Pathology and Laboratory (06) | 06.02.27m | 06.02.27 | cdfe1bab-26bc-4f44-a661-53aad9aaf13b | Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (AmeriHealth Administrators) | Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (AmeriHealth Administrators) | |
| | | 3833 | AssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06i | Medicine (07) | 07.10.06i | 07.10.06 | 79b13a12-1743-4991-8438-7312e26bd409 | Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation | Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation | |
| | | 4114 | Atezolizumab(Tecentriq®)08.01.69b | Pharmacy (08) | 08.01.69b | 08.01.69 | 82b3e9e5-7ed1-47c0-813a-b54b0f5797a6 | Atezolizumab (Tecentriq®) | Atezolizumab (Tecentriq®) | {"4115": {"Id":4115,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6121,"PolicyAttachmentPageName":"1cacd22d-4763-4dae-917c-500de8069d0c"},} |
| | | 3788 | AutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(AmerihealthAdministrators)11.14.06j | Surgery (11) | 11.14.06j | 11.14.06 | cf94fedd-11fa-4401-a582-f18f4627fdf8 | Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Amerihealth Administrators) | Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Amerihealth Administrators) | |
| | | 3543 | AutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29l | DME (05) | 05.00.29l | 05.00.29 | 373f2389-2605-4718-bf5b-aeacb92edb77 | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | {"3544": {"Id":3544,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5694,"PolicyAttachmentPageName":"3ccd5fd1-0706-42ab-88c6-03117e474eb9"},"3545": {"Id":3545,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5695,"PolicyAttachmentPageName":"ca1a9677-3db6-45ab-a41c-de5902baad65"},} |
| | | 3989 | AutonomicNervousSystemTesting07.03.23e | Medicine (07) | 07.03.23e | 07.03.23 | dfd20b04-691f-46d9-8071-5b7cb3453f08 | Autonomic Nervous System Testing | Autonomic Nervous System Testing | |
| | | 4013 | Avelumab(Bavencio®)08.01.64a | Pharmacy (08) | 08.01.64a | 08.01.64 | 434a7d30-72aa-4ef4-ab31-7dfb73669346 | Avelumab (Bavencio®) | Avelumab (Bavencio®) | {"4014": {"Id":4014,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6026,"PolicyAttachmentPageName":"e759f4b7-37b6-43d6-a60d-a1d1b5f94081"},} |
| | | 3839 | BalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitis11.16.06j | Surgery (11) | 11.16.06j | 11.16.06 | 5c324c9e-38cd-4d6f-bdc0-7c5ac6a15b2e | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | |
| | | 2824 | BariatricSurgery11.03.02t | Surgery (11) | 11.03.02t | 11.03.02 | deb6788b-9378-4634-bea1-f71971bb7026 | Bariatric Surgery | Bariatric Surgery | {"2825": {"Id":2825,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":4907,"PolicyAttachmentPageName":"1ae6209c-f0da-459c-adb3-cace9e40b535"},"2826": {"Id":2826,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":4908,"PolicyAttachmentPageName":"3fc8cbfa-375e-4a3f-a769-c3bd36fe1065"},"2827": {"Id":2827,"MPAttachmentLetter":"C","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":4909,"PolicyAttachmentPageName":"778a747c-2dd7-41ec-a720-71eec3fa4351"},} |
| | | 4276 | Belantamabmafodotin-blmf(Blenrep)08.01.70b | Pharmacy (08) | 08.01.70b | 08.01.70 | 246806c0-46da-409c-b330-cdc5192c284a | Belantamab mafodotin-blmf (Blenrep) | Belantamab mafodotin-blmf (Blenrep) | |
| | | 4103 | Belimumab(Benlysta®)forIntravenousUse08.00.99d | Pharmacy (08) | 08.00.99d | 08.00.99 | 1473376c-e0a2-4e8b-ab41-a63e294f68a6 | Belimumab (Benlysta®) for Intravenous Use | Belimumab (Benlysta®) for Intravenous Use | |
| | | 4106 | Bevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66q | Pharmacy (08) | 08.00.66q | 08.00.66 | 5062db65-0522-438f-ace1-ea10b9a34423 | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | {"4107": {"Id":4107,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":6016,"PolicyAttachmentPageName":"b4293c8f-a019-4fc9-9567-c1419c7fc8c0"},} |
| | | 4031 | BillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39o | Administrative (00) | 00.10.39o | 00.10.39 | 93563ead-a585-4c93-a945-499bd6f8709f | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | {"4032": {"Id":4032,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":6119,"PolicyAttachmentPageName":"7663b74d-b1a0-45bb-9e6a-d8c158edf943"},} |
| | | 3087 | BillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38a | Administrative (00) | 00.10.38a | 00.10.38 | e862bc0b-0289-4661-bf0a-950e2efca6ee | Billing Requirements for Multiple Births for Professional Providers | Billing Requirements for Multiple Births for Professional Providers | {"3088": {"Id":3088,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5340,"PolicyAttachmentPageName":"ba5b6730-4f52-4c93-97c1-4ca8f4766879"},"3089": {"Id":3089,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5341,"PolicyAttachmentPageName":"494d41d3-1fd0-4df8-b729-ad76b6fc2723"},"3090": {"Id":3090,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5342,"PolicyAttachmentPageName":"1232f148-ec02-4366-a47a-8917edfa3d73"},"3091": {"Id":3091,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5343,"PolicyAttachmentPageName":"dee47969-1193-42f8-9cc1-4dabfcc50995"},} |
| | | 3724 | BiofeedbackTherapy07.00.01j | Medicine (07) | 07.00.01j | 07.00.01 | e2f75216-10d2-49bf-80f5-c9cd836a8ff0 | Biofeedback Therapy | Biofeedback Therapy | |
| | | 3362 | BioimpedencefortheDetectionofLymphedema07.06.03b | Medicine (07) | 07.06.03b | 07.06.03 | cd8cf796-b592-420d-9cab-8d2f79ac5dd4 | Bioimpedence for the Detection of Lymphedema | Bioimpedence for the Detection of Lymphedema | |
| | | 3824 | Blepharoplasty,RepairofBlepharoptosis,RepairofBrowPtosis,andCanthoplasty/Canthopexy11.05.02j | Surgery (11) | 11.05.02j | 11.05.02 | ad5e9419-4c7a-4e80-a765-be53cf4cd729 | Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy | Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy | {"3825": {"Id":3825,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5915,"PolicyAttachmentPageName":"b45f6745-e809-4139-af36-cf3eec5e9add"},} |
| | | 3329 | Blinatumomab(Blincyto®)08.01.21d | Pharmacy (08) | 08.01.21d | 08.01.21 | 6e7ed1b5-34ce-4ae4-b8dc-de98c39b1693 | Blinatumomab (Blincyto®) | Blinatumomab (Blincyto®) | |
| | | 4041 | Bone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06f | Surgery (11) | 11.01.06f | 11.01.06 | a04154ab-caaf-4033-ab58-95e6f7fcee3b | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | |
| | | 3967 | BoneMineralDensity(BMD)Testing09.00.04l | Radiology (09) | 09.00.04l | 09.00.04 | 1424659b-6e13-4b6d-9b0d-0c00f2437685 | Bone Mineral Density (BMD) Testing | Bone Mineral Density (BMD) Testing | |
| | | 4188 | Bortezomib(BortezomibforInjection,Velcade®)08.00.73n | Pharmacy (08) | 08.00.73n | 08.00.73 | 1c1bf17a-c01a-4fdc-9e69-0c07a8e32ef7 | Bortezomib (Bortezomib for Injection, Velcade®) | Bortezomib (Bortezomib for Injection, Velcade®) | {"4189": {"Id":4189,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6196,"PolicyAttachmentPageName":"e25514cf-6a0d-4875-af9d-cc319c289069"},} |
| | | 4255 | BotulinumToxinAgents08.00.26y | Pharmacy (08) | 08.00.26y | 08.00.26 | c0537d15-4f42-47e4-9dbd-2d97caeb0ee7 | Botulinum Toxin Agents | Botulinum Toxin Agents | {"4256": {"Id":4256,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":6206,"PolicyAttachmentPageName":"3915e96a-1fe0-45d8-b763-9a9cb584b148"},} |
| | | 3078 | BrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy09.00.10z | Radiology (09) | 09.00.10z | 09.00.10 | 58a9dc62-6d10-446e-83de-88737485a3d1 | Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy | Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy | |
| | | 3903 | BreastPumps05.00.76e | DME (05) | 05.00.76e | 05.00.76 | 9be7e1b3-e90d-463a-8e7f-9b602aea3dad | Breast Pumps | Breast Pumps | |
| | | 3602 | BrentuximabVedotin(Adcetris®)08.01.13f | Pharmacy (08) | 08.01.13f | 08.01.13 | b1114295-dcd2-4db2-9f0b-05fb8b724540 | Brentuximab Vedotin (Adcetris®) | Brentuximab Vedotin (Adcetris®) | {"3603": {"Id":3603,"MPAttachmentLetter":"A","Title":"ICD CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5777,"PolicyAttachmentPageName":"7b530f88-1768-434e-ba75-5f6b3ccf446b"},} |
| | | 4141 | BronchialValves11.16.09 | Surgery (11) | 11.16.09 | 11.16.09 | 52cbba4a-1c34-44f4-852c-2aa2af748210 | Bronchial Valves | Bronchial Valves | |
| | | 4264 | Burosumab-twza(Crysvita®)08.01.49b | Pharmacy (08) | 08.01.49b | 08.01.49 | 7af88e8b-93a3-4f90-8d3c-0784954a941b | Burosumab-twza (Crysvita®) | Burosumab-twza (Crysvita®) | |
| | | 4128 | Canakinumab(Ilaris®)08.01.51a | Pharmacy (08) | 08.01.51a | 08.01.51 | 84e6f9ee-5c3e-4179-9c84-40caa2a7e7d6 | Canakinumab (Ilaris®) | Canakinumab (Ilaris®) | |
| | | 3727 | CardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01n | Rehabilitation Services (10) | 10.01.01n | 10.01.01 | 51849fc3-b6b2-4b18-9bb5-8d8b12e525c3 | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | {"3728": {"Id":3728,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5729,"PolicyAttachmentPageName":"df79dcbb-549e-4e94-abff-98120d1eedf3"},} |
| | | 4152 | CareManagementandCarePlanningServices00.01.59j | Administrative (00) | 00.01.59j | 00.01.59 | f2189574-3648-4c87-87b3-3cb4fd613f8a | Care Management and Care Planning Services | Care Management and Care Planning Services | |
| | | 3885 | Carfilzomib(Kyprolis®)08.01.05h | Pharmacy (08) | 08.01.05h | 08.01.05 | 8000f759-7cf7-41f7-9f5c-9fec82cfe349 | Carfilzomib (Kyprolis®) | Carfilzomib (Kyprolis®) | |
| | | 2815 | CastandSplintApplicationsandAssociatedSupplies00.10.15d | Administrative (00) | 00.10.15d | 00.10.15 | ead5d815-c736-402d-a236-12375fa27c39 | Cast and Splint Applications and Associated Supplies | Cast and Splint Applications and Associated Supplies | {"2816": {"Id":2816,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":4979,"PolicyAttachmentPageName":"8e789d63-630d-4491-95de-91c11ca83242"},} |
| | | 3990 | CataractSurgery11.01.07f | Surgery (11) | 11.01.07f | 11.01.07 | 0127f7e1-d5a9-4dff-a9de-d30cca593715 | Cataract Surgery | Cataract Surgery | {"3991": {"Id":3991,"MPAttachmentLetter":"A","Title":"ICD 10 codes for policy 11.01.07d, Cataract Surgery","MPPolicyAttachmentInternalSourceId":6072,"PolicyAttachmentPageName":"4401bd85-8ea3-4169-aca4-37ff08cf69f3"},} |
| | | 3996 | CatheterAblationofCardiacArrhythmias11.02.06n | Surgery (11) | 11.02.06n | 11.02.06 | c8fb9adf-c491-46e9-85b0-f15a282f509a | Catheter Ablation of Cardiac Arrhythmias | Catheter Ablation of Cardiac Arrhythmias | |
| | | 4017 | Cemiplimab-rwlc(Libtayo®)08.01.66a | Pharmacy (08) | 08.01.66a | 08.01.66 | 5704d820-a99c-4ae5-beea-0a82cca6d121 | Cemiplimab-rwlc (Libtayo®) | Cemiplimab-rwlc (Libtayo®) | |
| | | 4266 | Cerliponasealfa(Brineura®)08.01.39c | Pharmacy (08) | 08.01.39c | 08.01.39 | e6a2d37b-275f-4667-80c4-f1aa67d76f95 | Cerliponase alfa (Brineura®) | Cerliponase alfa (Brineura®) | |
| | | 4180 | CervicalTractionDevicesforIn-homeUse05.00.61g | DME (05) | 05.00.61g | 05.00.61 | 19abc466-a082-44c4-b559-60ac37f1d500 | Cervical Traction Devices for In-home Use | Cervical Traction Devices for In-home Use | |
| | | 3551 | Cetuximab(Erbitux®)08.00.67m | Pharmacy (08) | 08.00.67m | 08.00.67 | 97676303-7d9b-4fac-b144-cbb4ef0f89d2 | Cetuximab (Erbitux®) | Cetuximab (Erbitux®) | {"3552": {"Id":3552,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":5391,"PolicyAttachmentPageName":"3f23c274-c8fa-4f74-992f-419fcccc78e1"},"3553": {"Id":3553,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5392,"PolicyAttachmentPageName":"0390ff2e-893c-41d9-9f68-98b2f9cce4bc"},} |
| | | 3567 | ChemicalPeels11.08.08g | Surgery (11) | 11.08.08g | 11.08.08 | a47d58ff-608b-44de-aa95-33eacd21c307 | Chemical Peels | Chemical Peels | |
| | | 3979 | ChimericAntigenReceptor(CAR)Therapy08.01.43j | Pharmacy (08) | 08.01.43j | 08.01.43 | f831705f-1372-45a4-a683-340250445ddb | Chimeric Antigen Receptor (CAR) Therapy | Chimeric Antigen Receptor (CAR) Therapy | {"3980": {"Id":3980,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6115,"PolicyAttachmentPageName":"3cd16772-be0e-4e1a-91fc-4d425322b6dd"},} |
| | | 3311 | ChiropracticSpinalandExtraspinalManipulationTherapy10.02.02j | Rehabilitation Services (10) | 10.02.02j | 10.02.02 | 79223218-5ff1-491f-aae1-eb232d8fa401 | Chiropractic Spinal and Extraspinal Manipulation Therapy | Chiropractic Spinal and Extraspinal Manipulation Therapy | |
| | | 3773 | CoagulationFactors08.00.92ad | Pharmacy (08) | 08.00.92ad | 08.00.92 | 1c1ff6fe-09b9-436b-bf31-352aed9cc2d9 | Coagulation Factors | Coagulation Factors | |
| | | 3895 | Cobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54b | Pathology and Laboratory (06) | 06.02.54b | 06.02.54 | b53dc01a-b63f-4cd6-95b7-a214349dff14 | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | {"3896": {"Id":3896,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":6108,"PolicyAttachmentPageName":"ba460233-61a2-414c-90dd-c9876003b9d7"},} |
| | | 3164 | CochlearImplant11.01.02p | Surgery (11) | 11.01.02p | 11.01.02 | e4d1c502-60ae-4c63-8021-a778a10a3c5d | Cochlear Implant | Cochlear Implant | |
| | | 4178 | Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo™)08.01.71 | Pharmacy (08) | 08.01.71 | 08.01.71 | 71f01bda-41b7-46f8-b05c-e931c2151821 | Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™) | Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™) | |
| | | 3897 | ColorectalCancerScreening11.03.12t | Surgery (11) | 11.03.12t | 11.03.12 | 21915e7a-f45a-4006-aab9-6b31af07abe7 | Colorectal Cancer Screening | Colorectal Cancer Screening | |
| | | 1917 | Complementary and Integrative Health Services | Miscellaneous (12) | 12.00.03g | 12.00.03 | B55889244594F1F085258574005DA579 | Complementary and Integrative Health Services | Complementary and Integrative Health Services | |
| | | 3371 | CompleteDecongestiveTherapy(CDT)07.06.01b | Medicine (07) | 07.06.01b | 07.06.01 | 335f806f-5741-4098-9952-55b12dc1e476 | Complete Decongestive Therapy (CDT) | Complete Decongestive Therapy (CDT) | |
| | | 3239 | CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30 | Surgery (11) | 11.14.30 | 11.14.30 | c4cb29d5-a6d2-451f-9cb0-66bc9d495580 | Composite Tissue Allotransplantation of the Hand(s) and Face | Composite Tissue Allotransplantation of the Hand(s) and Face | |
| | | 3237 | CompressionGarments05.00.37f | DME (05) | 05.00.37f | 05.00.37 | d7412bfb-d233-41cb-abab-b9e378c4702b | Compression Garments | Compression Garments | |
| | | 3575 | Computer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42c | Radiology (09) | 09.00.42c | 09.00.42 | 742c5690-7789-4c49-a3c4-f7fd8d3f4b9b | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | |
| | | 3241 | Computer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17e | Surgery (11) | 11.14.17e | 11.14.17 | cea741ca-e1f5-411d-8d34-6af7ac2699a5 | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | |
| | | 1986 | Consultation Services | Administrative (00) | 00.01.69 | 00.01.69 | F3BA7DB0E980312B8525854B005EE64C | Consultation Services | Consultation Services | |
| | | 4282 | ContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11k | Medicine (07) | 07.13.11k | 07.13.11 | 1c569fa6-371f-4b4b-9200-c3ab329590bd | Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects | Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects | {"4283": {"Id":4283,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6289,"PolicyAttachmentPageName":"9f12f63f-88f6-416e-8633-2dea34950404"},} |
| | | 3132 | ContrastAgentsUsedinConjunctionwithEchocardiography09.00.11e | Radiology (09) | 09.00.11e | 09.00.11 | 6559b183-cc4e-4272-9c94-1515a87d738a | Contrast Agents Used in Conjunction with Echocardiography | Contrast Agents Used in Conjunction with Echocardiography | |
| | | 3827 | CornealPachymetryUsingUltrasound07.13.07k | Medicine (07) | 07.13.07k | 07.13.07 | c662c386-f536-47e5-b61c-97ecd3c341c2 | Corneal Pachymetry Using Ultrasound | Corneal Pachymetry Using Ultrasound | {"3828": {"Id":3828,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":5964,"PolicyAttachmentPageName":"47db5a9e-338f-4417-b2b5-6fd865c465a7"},} |
| | | 3370 | CosmeticProcedures12.01.03a | Miscellaneous (12) | 12.01.03a | 12.01.03 | 3fbb0f4b-f2c3-4e5e-8f16-ed646b2faaaf | Cosmetic Procedures | Cosmetic Procedures | |
| | | 4163 | CoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08h | Pharmacy (08) | 08.01.08h | 08.01.08 | be1d6603-25f7-4fee-add7-123d29eea45a | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | {} |
| | | 3720 | CoverageofMedicalDevices05.00.04e | DME (05) | 05.00.04e | 05.00.04 | 14669bc5-097a-4a2c-bbf0-82a2e0da5a62 | Coverage of Medical Devices | Coverage of Medical Devices | |
| | | 3864 | CranialElectrotherapyStimulation05.00.80a | DME (05) | 05.00.80a | 05.00.80 | b3fb682c-aef5-4ba3-b62c-b8bf75862601 | Cranial Electrotherapy Stimulation | Cranial Electrotherapy Stimulation | |
| | | 4130 | CranialRemoldingOrthoses(Helmets)05.00.25i | DME (05) | 05.00.25i | 05.00.25 | 50ef9336-43ce-4d9b-a4dc-3e43464b5847 | Cranial Remolding Orthoses (Helmets) | Cranial Remolding Orthoses (Helmets) | |
| | | 1811 | Criteria for Reimbursement of Emergency Room Services | Administrative (00) | 00.10.03j | 00.10.03 | 85256AA800623D7A852584710058EC0E | Criteria for Reimbursement of Emergency Room Services | Criteria for Reimbursement of Emergency Room Services | |
| | | 4112 | crizanlizumab-tmca(Adakveo®)08.00.04 | Pharmacy (08) | 08.00.04 | 08.00.04 | 06c04256-2595-4568-b588-ffe96ce41f54 | crizanlizumab-tmca (Adakveo®) | crizanlizumab-tmca (Adakveo®) | |
| | | 3245 | CryosurgicalAblationoftheProstateGland11.11.03d | Surgery (11) | 11.11.03d | 11.11.03 | f8864ad8-763e-4de5-b347-c1e53faf3f62 | Cryosurgical Ablation of the Prostate Gland | Cryosurgical Ablation of the Prostate Gland | |
| | | 3331 | Daratumumab(Darzalex®),Daratumumab,andHyaluronidase-fihj(DarzalexFaspro®)08.01.29i | Pharmacy (08) | 08.01.29i | 08.01.29 | caddc052-448d-47ed-ab6a-9038bbc469d3 | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | |
| | | 3395 | DayRehabilitation10.00.02c | Rehabilitation Services (10) | 10.00.02c | 10.00.02 | d93acb77-0d6c-4707-bd4a-443705511a77 | Day Rehabilitation | Day Rehabilitation | |
| | | 3661 | DebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNails11.08.17k | Surgery (11) | 11.08.17k | 11.08.17 | 62e02374-fa4f-44d0-92b6-3997cb88b0f8 | Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails | Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails | {"3662": {"Id":3662,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":5830,"PolicyAttachmentPageName":"09cba037-fe5b-44bd-95c1-4c5f17735ab3"},"3663": {"Id":3663,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":5831,"PolicyAttachmentPageName":"e29503f8-2b54-40c1-94ef-82ed8b67fcf3"},"3664": {"Id":3664,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":5832,"PolicyAttachmentPageName":"6e702f6f-06ff-4f91-8aa7-bba38a5ab170"},"3665": {"Id":3665,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":5833,"PolicyAttachmentPageName":"21bd345c-09b8-4b9d-b00a-4fde9762d077"},"3666": {"Id":3666,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":5834,"PolicyAttachmentPageName":"90fe240d-525c-48dc-896a-10b3f43608a0"},} |
| | | 3782 | DeepBrainStimulation(DBS)11.15.20p | Surgery (11) | 11.15.20p | 11.15.20 | a0a1c930-20bc-4e8a-b8d7-f758d46ef324 | Deep Brain Stimulation (DBS) | Deep Brain Stimulation (DBS) | |
| | | 3826 | DenervationoftheSpinalNervesforChronicPain(AmerihealthAdministrators)11.15.09p | Surgery (11) | 11.15.09p | 11.15.09 | 15a55608-5674-4b6c-8aac-afbe4e94dc43 | Denervation of the Spinal Nerves for Chronic Pain (Amerihealth Administrators) | Denervation of the Spinal Nerves for Chronic Pain (Amerihealth Administrators) | |
| | | 4262 | Denosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)08.00.94p | Pharmacy (08) | 08.00.94p | 08.00.94 | a59431fc-4e4a-4555-bd20-86abeafad4c3 | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | {"4263": {"Id":4263,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":6188,"PolicyAttachmentPageName":"0aaab259-024d-41d0-8f45-e4c2db3936e2"},} |
| | | 3986 | DermabrasionforRhinophyma,Septoplasty,Rhinoplasty,andSeptorhinoplasty11.16.01i | Surgery (11) | 11.16.01i | 11.16.01 | 26f68069-1450-4dc9-9b2e-95793e7d448c | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | |
| | | 4054 | DiagnosticRadiologyServicesIncludedinCapitation00.03.02ac | Administrative (00) | 00.03.02ac | 00.03.02 | 1afb2669-3344-48df-9b54-8fa9095f0681 | Diagnostic Radiology Services Included in Capitation | Diagnostic Radiology Services Included in Capitation | {"4055": {"Id":4055,"MPAttachmentLetter":"A","Title":"Diagnostic Radiology Procedure Codes Included in Capitation for Pennsylvania (PA) Health Maintenance Organization (HMO) Members","MPPolicyAttachmentInternalSourceId":6155,"PolicyAttachmentPageName":"cd621f4f-943a-47a7-9bea-9aacf41b6504"},} |
| | | 4052 | DirectAccesstoObstetrics/Gynecology(OB/GYN)Services00.09.01i | Administrative (00) | 00.09.01i | 00.09.01 | 898829fe-3262-4d01-9c71-4f71ed3a563d | Direct Access to Obstetrics/Gynecology (OB/GYN) Services | Direct Access to Obstetrics/Gynecology (OB/GYN) Services | {} |
| | | 3252 | Dofetilide(Tikosyn®)UseintheInpatientSetting08.00.49e | Pharmacy (08) | 08.00.49e | 08.00.49 | 46492617-4cbd-442b-a4e2-b29e7eee784d | Dofetilide (Tikosyn®) Use in the Inpatient Setting | Dofetilide (Tikosyn®) Use in the Inpatient Setting | |
| | | 4137 | Dostarlimab-gxly(Jemperli)08.01.79c | Pharmacy (08) | 08.01.79c | 08.01.79 | 14bced08-e2b4-42b3-a1ee-4baa5f9c9cef | Dostarlimab-gxly (Jemperli) | Dostarlimab-gxly (Jemperli) | |
